Real Psilocybin2022-07-25T10:42:00+02:00

Informed by nature
and guided by science

Informed
by nature

and guided
by science

Pioneering the use of natural psychedelics for mental health

We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.

About Us

Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.

We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment.

We operate one of the first federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world.

Our range of functional mushroom wellness products harness the power of adaptogens – non-toxic, non-psychoactive plants used in ancient medicine for their stress relieving and general wellness benefits.

Learn More

Bringing together leaders in the business of medicine and science

Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.

Our Team

Our News

VIEW ALL

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Contact Us

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Contact Us

Our News

  • GOODMIND_FEATURE

GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.

November 29, 2022|

Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.

Psyence Group Announces Strategic Private Placement

November 10, 2022|

Psyence announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium led by Brandon Kerzner, a member of the globally recognised Kerzner family. Brandon has a focus on investing in technology and life science advancement industries.

VIEW ALL
Go to Top